Incyte Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC, reporting a net loss of $784.8 million for the third quarter driven by a sharp increase in research and development expenses.

Key Highlights

  • Net loss of $784.8 million in Q3 2026, compared to net income of $424.2 million in Q3 2025, according to the filing.
  • Total revenues of $1.557 billion for Q3 2026, up from $1.366 billion in Q3 2025, driven by net sales of $1.316 billion and product royalty revenues of $190.9 million.
  • R&D expenses surged to $1.792 billion in Q3 2026, compared to $506.6 million in Q3 2025, the filing disclosed.
  • Nine-month net income of $104.1 million on total revenues of $4.504 billion for the nine months ended September 30, 2026.
  • Cash and cash equivalents of $3.276 billion as of September 30, 2026, up from $3.098 billion at December 31, 2025.
  • 203,832,492 shares outstanding as of October 22, 2026, per the filing's cover page.

Incyte Reports Q3 2026 Operating Loss Amid Sharp R&D Cost Increase

According to the Form 10-Q filed by Incyte Corporation (NASDAQ:INCY) for the quarterly period ended September 30, 2026, the company reported a net loss of $784.8 million, or $3.86 per basic and diluted share, compared to net income of $424.2 million, or $2.11 per diluted share, in the same quarter of 2025. The filing attributes the swing primarily to a substantial rise in research and development expenses, which reached $1.792 billion in Q3 2026 versus $506.6 million in Q3 2025.

Total revenues for the third quarter grew to $1.557 billion from $1.366 billion in Q3 2025. Net sales accounted for $1.316 billion of that total, up from $1.150 billion a year earlier. Product royalty revenues were $190.9 million, and milestone and contract revenues were $49.8 million, the filing reported. Selling, general and administrative expenses were $364.3 million for Q3 2026 versus $329.1 million in Q3 2025. The loss from operations for Q3 2026 was $708.4 million, compared to income from operations of $443.5 million in Q3 2025.

For the nine months ended September 30, 2026, the company reported net income of $104.1 million, or $0.50 per diluted share, on total revenues of $4.504 billion, compared to net income of $987.4 million on revenues of $3.634 billion for the same period in 2025. The nine-month results also included asset impairment and related disposal costs of $23.2 million with no comparable charge in 2025. On the balance sheet as of September 30, 2026, total assets were $7.287 billion and total stockholders' equity was $5.643 billion. Common shares issued and outstanding were 204,002,500 as of September 30, 2026, compared to 198,460,009 at December 31, 2025.

What Was Disclosed

Incyte Corporation disclosed its unaudited condensed consolidated financial statements for Q3 2026, showing a quarterly net loss of $784.8 million, nine-month net income of $104.1 million, total assets of $7.287 billion, and cash and equivalents of $3.276 billion as of September 30, 2026.